Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...

PFG Investments LLC decreased its holdings in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 11.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned ...

Geneos Wealth Management Inc. raised its holdings in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 826.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...